OQROGet OQRO Pro
Insider trade

Incyte (INCY)Officer sold ~$2.06M

Steven H Stein, Officer at Incyte, sold ~$2.06M of Incyte shares.

~$2.06M
Approx. value · 20K sh @ $102.51
63K
Holds after · shares reported
Traded
Dec 2, 2025
Filed
Dec 3, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 30, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 30, 2025, the Board of Directors of Incyte Corporation (the “Company”) appointed Thomas Tray, the Company’s current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025.”
  2. Oct 2, 2025InsiderOfficer sold ~$53K of INCY shares in the open market
  3. Oct 3, 2025InsiderOfficer sold ~$299K of INCY shares in the open market
  4. Oct 15, 2025InsiderOfficer sold ~$24K of INCY shares in the open market
  5. Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 7.8%
  6. Oct 28, 2025Company filing · Form 8-K · ResultsReported its results
  7. Nov 3, 2025InsiderOfficer sold ~$289K of INCY shares in the open market
  8. Nov 4, 2025InsiderOfficer sold ~$61K of INCY shares in the open market
  9. Nov 5, 2025InsiderOfficer sold ~$535K of INCY shares in the open market
  10. Nov 10, 20255% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.0%
  11. Nov 10, 2025Insider · Their largest sale since 2017Director sold ~$19.8M of INCY shares in the open market
  12. Nov 17, 2025InsiderOfficer sold ~$29K of INCY shares in the open market
  13. Nov 21, 2025InsiderOfficer sold ~$17K of INCY shares in the open market
  14. Nov 24, 2025InsiderOfficer sold ~$62K of INCY shares in the open market
  15. Dec 1, 2025InsiderOfficer sold ~$263K of INCY shares in the open market
  16. Dec 2, 2025 · this disclosureInsider · 8 days before an 8-KOfficer sold ~$2.06M of INCY shares in the open market

What came next

  1. Dec 10, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately.”
  2. Dec 10, 2025InsiderOfficer sold ~$531K of INCY shares in the open market
  3. Dec 11, 2025InsiderOfficer sold ~$24K of INCY shares in the open market
  4. Dec 16, 2025Insider · 1 personInsiders: 2 sales (~$5.3M)
  5. Dec 17, 2025FDAFDA drug approval: Zynyz
  6. Dec 17, 2025InsiderOfficer sold ~$420K of INCY shares in the open market
  7. Dec 18, 2025InsiderOfficer sold ~$59K of INCY shares in the open market
  8. Dec 19, 2025InsiderOfficer sold ~$277K of INCY shares in the open market
  9. Jan 5, 2026InsiderOfficer sold ~$1.59M of INCY shares in the open market
  10. Jan 7, 2026InsiderOfficer sold ~$1.18M of INCY shares in the open market
  11. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
  12. Feb 10, 20265% stakeFelix J. Baker filed an activist stake (13D) of 15.7%
  13. Feb 19, 2026InsiderOfficer sold ~$1.88M of INCY shares in the open market
  14. Mar 17, 2026Insider · 8 days before an 8-KOfficer sold ~$1.76M of INCY shares in the open market
  15. Mar 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately.”
  16. Mar 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026.”
  17. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  18. Mar 30, 2026FDAFDA drug approval: Zynyz
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Incyte

For Incyte, OQRO holds 23 insider filings (SEC Form 4 or Form 144) and 14 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its INCY page.

Other recent filings by Steven H Stein, EVP & Chief Medical Officer

The full history of Steven H Stein, EVP & Chief Medical Officer is on the profile page.

How this filing works

Other disclosures at Incyte

Everything OQRO holds on this company is on its INCY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data